ClinicalTrials.gg
RecruitingNCT07117435Updated Aug 12, 2025

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

A Phase 1 interventional study of paclitaxel cationic liposome for injection and Oxaliplatin in Colorectal Liver Metastases and First-line Treatment, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 63 studies testing oxaliplatin in Neoplasm Metastasis — 6 open to participants now, 7 under way, none of them phase 3. Oxaliplatin · Neoplasm Metastasis.

Planned enrollment
55th of 60
7 · median 44
Started
2025
the only one that year
Phase 1
12 of 63
3 open now
Registered
63rd of 63
by date

Among the 63 studies testing oxaliplatin in Neoplasm Metastasis, this one is the 55th largest by planned enrollment of the 60 interventional ones that give a count, is the only one that started in 2025, is one of 12 in phase 1, and was the 63rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 892 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 63 studies testing oxaliplatin in Neoplasm Metastasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing oxaliplatin in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This is a phase Ib/III, randomized, multicenter study evaluating the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.

Read the detailed description

This study includes 2 parts. In Phase Ib part of this study, paclitaxel cationic liposome was administered via hepatic arterial infusion on Day 15 of each 3-week cycle, and in a gradual increment dose from the low-level to the high-level, with the first cycle (21 days) being the DLT observation period. In the Phase III part of this study, participants will be randomized in 1:1 ratio to receive either hepatic arterial infusion of paclitaxel cationic liposome (at the dose to be determined in the Phase Ib) in combination with systemic therapy or systemic therapy.

The primary purpose of the Phase Ib part of this study is to determine the recommended Phase III dose (RP3D) of paclitaxel cationic liposome administered via hepatic arterial infusion on Day 15 of each 3-week cycle.

The primary purpose of the Phase III part of this study is to measure the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.

03

Conditions studied

  • Colorectal Liver Metastases
  • First-line Treatment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age range: 18 - 75 years old (inclusive), gender not limited.
  • 2. For patients with colorectal liver have been or cytologically confirmed and who are assessed by multidisciplinary team (MDT) to be inoperable for radical surgical resection:

    1. Have not received systemic treatment for the metastatic or recurrent disease;
    2. For patients who have received /adjuvant therapy before, the time interval between the last administration and disease progression must be ≥ 6 months;
    3. Allow patients who have received local treatment and progressed.
  • 3. According to v1.1, at least one in the hepatic arterial infusion area (long diameter ≥ 1 cm and no previous local treatment).
  • 4. (ECOG) performance status score of 0-1.
  • 5. of at least 3 months.
  • 6. Adequate organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factors within 14 days)
  • 7. Fertile patients (male and female) must agree to use reliable methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study intervention. Women of must have a negative pregnancy test within 7 days prior to enrollment.
  • 8. Fully understand the clinical study and voluntarily sign a written form.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients known to have microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR), and have been evaluated by the investigators to be eligible for therapy.
  • 2. Patients known to have wild-type RAS and BRAF, and have been evaluated by the investigators to be eligible for anti-epidermal growth factor receptor (EGFR) drug therapy.
  • 3. Unresolved adverse reactions from previous anti-tumor treatments not yet recovered to 5.0 grade ≤ 1 (except for alopecia or other toxicities deemed non-risky by the investigators).
  • 4. Central nervous system with clinical symptoms, or meningeal metastasis, or there are other evidences indicating that the patient's central nervous system metastasis or meningeal metastatic lesions have not been controlled, and the investigators judges that the patient is not suitable for enrollment.
  • 5. Patients with for transcatheter arterial infusion.
  • 6. Patients with active infections within 2 weeks prior to administration (NCI CTC AE v5.0 ≥ grade 2) (Defined as requiring intravenous administration of antibacterial, antifungal or antiviral drugs for treatment).
  • 7. Patients with grade 2 or above peripheral neuropathy (NCI CTC AE v5.0).
  • 8. Patients with a history of diseases, immunodeficiency disorders, including positive test results, or suffering from other acquired or congenital immune deficiencies, or those currently using agents.
  • 9. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with HBV DNA ≥ 2×103 IU/mL (can use continuous antiviral treatment); or anti- virus antibody (HCV-Ab) positive with HCV RNA above the measurable limit; or active syphilis.
  • 10. Patients with known contraindications to capecitabine or oxaliplatin, paclitaxel or cationic liposome, or have severe allergic reactions; note: If the subject has contraindications to bevacizumab or has severe allergic reactions to any component of bevacizumab, it will not affect the enrollment but should not use bevacizumab in the study, and the specific reasons need to be recorded.
  • 11. Patients need to receive strong inducers and strong inhibitors of CYP2C8 and within 2 weeks before the first study treatment or during the treatment.
  • 12. Patients had or have non-infectious pneumonia/interstitial lung disease that requires systemic treatment.
  • 13. Severe cardiovascular disease history, including but not limited to:

    • Long syndrome;
    • High-degree atrioventricular block;
    • Severe arrhythmia that is not well controlled by medication;
    • Chronic heart failure history and cardiac function classification ≥ 3;
    • Severe valvular regurgitation or stenosis that requires treatment;
    • Acute coronary syndrome or severe myocardial disease within 6 months before screening;
    • Uncontrolled hypertension;
    • Echocardiography suggests \< 50%;
  • 14. Patients with a previous history of severe neurological or mental disorders (including epilepsy or dementia) lead to compliance issues.
  • 15. Patients with ultrasound-detected limb vascular thrombosis with potentially serious consequences during screening, or who with thromboembolic events within 3 months prior to enrollment.
  • 16. Patients with a history of severe bleeding, or who experienced major bleeding events such as intracranial hemorrhage, gastrointestinal bleeding, or purpura within the last 3 months.
  • 17. Any other reasons deemed by the investigators.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Paclitaxel cationic liposome was administered via hepatic arterial infusion on Day 15 of each 3-week cycle, and in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2, combined with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab)

    Drug: paclitaxel cationic liposome for injection · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Bevacizumab

Interventions

  • Drugpaclitaxel cationic liposome for injection

    Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2

  • Oxaliplatin 130 mg/m2 i.v. on D1

  • Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14

  • Bevacizumab 7.5 mg/kg i.v. on D1

06

What researchers measure

Primary outcomes

  1. The incidence of dose-limiting toxicity(DLT )

    Time frame: The first Cycle(21 days)

  2. Incidence and severity of AEs and SAEs (according to NCI-CTCAE 5.0)

    Time frame: Up to approximately 1 years

Secondary outcomes

  1. AUC0-t

    Time frame: The first four cycles ( each cycle is 21 days)

  2. AUC0-∞

    Time frame: The first four cycles ( each cycle is 21 days)

  3. Cmax

    Time frame: The first four cycles ( each cycle is 21 days)

  4. Kel

    Time frame: The first four cycles ( each cycle is 21 days)

  5. Tmax

    Time frame: The first four cycles ( each cycle is 21 days)

  6. Vz

    Time frame: The first four cycles ( each cycle is 21 days)

  7. t1/2

    Time frame: The first four cycles ( each cycle is 21 days)

  8. CL

    Time frame: The first four cycles ( each cycle is 21 days)

  9. Overall response rate(ORR)

    Time frame: Up to approximately 1 years

  10. Disease control rate(DCR)

    Time frame: Up to approximately 1 years

  11. Duration of Response(DoR)

    Time frame: Up to approximately 1 years

  12. Progression-Free-Survival(PFS)

    Time frame: Up to approximately 2 years

  13. Time to Progression(TTP)

    Time frame: Up to approximately 2 years

  14. Overall survival(OS)

    Time frame: Up to approximately 3 years

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Sun Yat-sen University,Lishui Central Hospital
    Lishui, Zhejiang, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 7 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
May 13, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 1, 2026
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07117435
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
May 13, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Aug 12, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Capecitabine · Bevacizumab

Start the discussion